Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy

Pharmacogenomics J. 2008 Apr;8(2):113-6. doi: 10.1038/sj.tpj.6500468. Epub 2007 Aug 14.

Abstract

Several lines of evidence suggest that catechol-O-methyltransferase (COMT) may be associated with treatment response in depression. We conducted a study on 119 patients with treatment-refractory depression admitted consecutively for electroconvulsive therapy (ECT). The COMT high/high genotype leads to a higher enzyme activity and thus lowers dopaminergic activity in the prefrontal cortex. In the present sample, those homozygous to high-active allele of COMT responded significantly more frequently to ECT.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Catechol O-Methyltransferase / genetics*
  • Depressive Disorder, Major / enzymology
  • Depressive Disorder, Major / genetics
  • Depressive Disorder, Major / therapy*
  • Electroconvulsive Therapy*
  • Female
  • Gene Expression Regulation, Enzymologic*
  • Gene Frequency
  • Homozygote
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Genetic*
  • Psychiatric Status Rating Scales
  • Treatment Outcome

Substances

  • Catechol O-Methyltransferase